Integra LifeSciences Holdings Corporation

NASDAQ:IART

Medical - Devices

Healthcare
$13.86 +4.71%

+$0.81 today

Market cap
$1.08B
Beta
1.25
P/E (TTM)
-2.8
EPS (TTM)
-$6.44
52W Low $8.70High $18.26

Volume 0.58M

Average 0.96M

IART Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Integra LifeSciences Holdings CorporationNASDAQ: IART

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $178.24M fell 1.8% year over year, ahead of the -4.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.3% from the prior quarter. Over 3 fiscal years it compounded at +4.3% a year.

Context

  • Selling, general & admin amounted to 42.8% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $693.17M (-0.9%) for the fiscal year ending Dec 2026, a step up from the -2.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$178.24M+5.3% QoQ
Last fiscal yearDec 2025
$699.7M-2.4% YoY
LTMMar 2026
$696.44M-4.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.8%-2.1%-0.3 pp
1 year-2.4%-0.9%+1.5 pp
3-year CAGR+4.3%+1.5%-2.8 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
699.7M USD
Year-over-year change
-2.4%
4-year CAGR
+2.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How IART compares with its peers on the latest reported figures

  • IART's LTM Mar 2026 selling, general & admin of $696.44M is the 4th highest of the 11 companies compared; the peer median is $507.96M.
  • Its year-over-year change of -4.9% is the 10th highest of 11, against a peer median of +5.6%.
  • Selling, general & admin amounts to 42.3% of revenue for IART, versus a peer median of 53.6%.
IART Competitors Peer median
Selling, General & Admin for IART and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$8.78B +11.0%+12.5%34.0%
SNNSmith & Nephew plcFY2025$3.04B +4.5%+3.9%49.3%
GMEDGlobus Medical, Inc.LTM Jun 2026$1.35B +30.2%+45.0%43.1%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$696.44M -4.9%+4.3%42.3%
OFIXOrthofix Medical Inc.LTM Mar 2026$555.96M +4.1%+13.9%67.4%
CNMDCONMED CorporationLTM Mar 2026$522.58M +4.9%+5.2%38.1%
ATECAlphatec Holdings, Inc.LTM Mar 2026$493.34M +6.4%+18.4%62.7%
AORTArtivion, Inc.LTM Mar 2026$220.91M +7.5%+10.6%48.2%
AXGNAxoGen, Inc.LTM Sep 2026$174.38M +34.8%+8.0%65.3%
TELATELA Bio, Inc.LTM Jun 2026$78.66M -0.6%+11.4%98.4%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$70.61M -7.6%+25.4%57.9%
Peer median (excluding IART) $507.96M+5.6%+11.9%53.6%

Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.54B1.56B1.54B1.61B1.64B
Cost of Revenue597.81M587.36M656.84M728.47M790.01M
Gross Profit944.64M970.31M884.74M882.06M845.23M
Gross Margin61.2%62.3%57.4%54.8%51.7%
Research & Development93.05M101.19M104.19M115.38M98.97M
Selling, General & Admin637.45M616.32M656.64M716.98M699.7M
Operating Expenses747.41M731.39M773.21M853.65M776.92M
Depreciation & Amortization123.67M121.12M123.51M140.5M151.05M
EBITDA366.33M384.6M255.96M193.29M(326.2M)
EBITDA Margin23.7%24.7%16.6%12.0%-19.9%
Operating Income197.23M238.92M111.53M28.41M68.32M
Operating Margin12.8%15.3%7.2%1.8%4.2%
Interest Income6.74M11.92M17.2M20.04M18.47M
Interest Expense50.4M49.59M51.38M70.63M86.26M
Other Income / Expenses17.45M(25.03M)(30.46M)(46.65M)(631.82M)
Income Before Tax214.68M213.89M81.07M(18.24M)(563.5M)
Pre-Tax Margin13.9%13.7%5.3%-1.1%-34.5%
Income Tax Expense45.6M33.34M13.33M(11.29M)(47.03M)
Net Income169.08M180.55M67.74M(6.94M)(516.47M)
Net Margin11.0%11.6%4.4%-0.4%-31.6%
EPS (Basic)2.002.180.87(0.09)(6.73)
EPS (Diluted)1.982.160.84(0.09)(6.73)
Weighted Avg Shares84.7M83M78.17M77.01M76.75M
Weighted Avg Shares (Diluted)85.49M83.52M80.34M77.01M76.75M

Integra LifeSciences Holdings Corporation

NASDAQ:IART

Intrinsic Alpha fair value

Locked

Current Price

$13.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.